[引用][C] Surrogate endpoints in pandemic preparedness
HJ de Grooth, JJ Parienti - The Journal of Infectious Diseases, 2024 - academic.oup.com
1. Parienti JJ, de Grooth HJ. Clinical relevance of nasopharyngeal SARS-CoV-2 viral load
reduction in outpatients with COVID-19. J Antimicrob Chemother 2022; 77: 2038–9. 2 …
reduction in outpatients with COVID-19. J Antimicrob Chemother 2022; 77: 2038–9. 2 …
[PDF][PDF] Potential conflicts of interest. The au
HJ de Grooth, JJ Parienti - Lancet Infect Dis, 2024 - scholar.archive.org
1. Parienti JJ, de Grooth HJ. Clinical relevance of nasopharyngeal SARS-CoV-2 viral load
reduction in outpatients with COVID-19. J Antimicrob Chemother 2022; 77: 2038–9. 2 …
reduction in outpatients with COVID-19. J Antimicrob Chemother 2022; 77: 2038–9. 2 …
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
SH Khoo, R Fitzgerald, T Fletcher… - Journal of …, 2021 - academic.oup.com
Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
Flaws in the Development and Validation of a Coronavirus Disease 2019 Prediction Model
GS Collins, RD Riley… - Clinical Infectious …, 2021 - academic.oup.com
1. Wong Y, Tse H, Siu HK, et al. Posterior oropharyngeal saliva for the detection of SARS-
CoV-2. Clin Infect Dis 2021; 71: 2939–46. 2. To KK, Tsang OT, Leung WS, et al. Temporal …
CoV-2. Clin Infect Dis 2021; 71: 2939–46. 2. To KK, Tsang OT, Leung WS, et al. Temporal …
Antiviral treatment for COVID-19: ensuring evidence is applicable to current circumstances
• Evidence from randomized controlled trials has shown that nirmatrelvir–ritonavir and
monulpiravir likely reduce the risk of severe COVID-19, hospital admission and death in …
monulpiravir likely reduce the risk of severe COVID-19, hospital admission and death in …
Real-world effectiveness of oral antivirals for COVID-19
C Burdet, F Ader - The Lancet, 2022 - thelancet.com
New orally bioavailable, direct-acting, antiviral therapeutics targeting RNA viruses including
SARS-CoV-2 have arrived. Molnupiravir and nirmatrelvir plus ritonavir were granted an …
SARS-CoV-2 have arrived. Molnupiravir and nirmatrelvir plus ritonavir were granted an …
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled …
SH Khoo, R FitzGerald, G Saunders… - The Lancet Infectious …, 2023 - thelancet.com
Background The antiviral drug molnupiravir was licensed for treating at-risk patients with
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
COVID-19 on the basis of data from unvaccinated adults. We aimed to evaluate the safety …
Response to Dawson et al
To the Editor—Dawson et al [1] raise 3 concerns about human challenge trials to assess the
efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. First …
efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. First …
Contributions to the mitigation of the COVID-19 pandemic
S Pilz - Clinical Infectious Diseases, 2024 - academic.oup.com
TO THE EDITOR—Kim et al [1] performed an excellent retrospective cohort study in 325 157
patients from the United States, showing that immunity from prior severe acute respiratory …
patients from the United States, showing that immunity from prior severe acute respiratory …